AbCellera’s ABCL635 cut hot flashes by 83%. Can the biotech turn Phase 2 success into a viable drug?
AbCellera heads to UBS after positive ABCL635 Phase 2 results and a $200 million financing. Examine its clinical and commercial priorities.
Pharma & Biotech
Pharma & Biotech
One ABCL635 injection cut hot flashes by 83%. Can AbCellera prove the benefit lasts?
AbCellera will reveal new ABCL635 safety and symptom data after reporting an 83% hot flash reduction. Can its antibody sustain the benefit?
Pharma & Biotech
Can one injection challenge daily hot-flash drugs? AbCellera’s ABCL635 faces its first real efficacy test
AbCellera will report Phase 2 ABCL635 data on Aug. 10, testing whether a long-acting NK3 antibody can reduce menopause hot flashes.
Pharma & Biotech
What AbCellera’s upcoming ABCL635 Phase 1 data could reveal about the future of menopause treatment
AbCellera will reveal Phase 1 ABCL635 data on May 11. Read why this menopause drug update could matter for investors and women’s health watchers.
Pharma & Biotech
Can ABCL635 redefine non-hormonal menopause treatment? Inside AbCellera’s Phase 2 push
AbCellera advances ABCL635 into Phase 2 for hot flashes. Find out what this means for non-hormonal menopause care and the biotech’s GPCR strategy.